Seabrook
Seabrook
Seabrook, Texas, United States7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Cushing syndrome, Nutritional and Metabolic Diseases, Paraneoplastic Endocrine Syndromes, adrenal gland disorder, adrenal gland hyperfunction, diabetes mellitus, ectopic ACTH secretion syndrome, endocrine system disorder, glucose metabolism disease, metabolic disease, neoplasm, paraneoplastic syndrome, type 2 diabetes mellitus | Recruiting | Phase 2 | 2026-10-06 | NCT07296484 | |
| A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-09-17 | NCT07221188 | |
| A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | Infections, RNA Virus Infections, influenza, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease | Active, not recruiting | Phase 3 | 2026-09-17 | NCT07159763 | |
| A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-07-27 | NCT07221227 | |
| A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Graves Ophthalmopathy, Graves disease, autoimmune disease, disease of orbital part of eye adnexa, endocrine system disorder, exophthalmos, eye disorder, goiter, hereditary disease, hyperthyroidism, immune system disorder, thyroid gland disorder | Active, not recruiting | Phase 3 | 2026-05-22 | NCT06812325 | |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Body Weight, Body Weight Changes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss | Active, not recruiting | Phase 3 | 2026-04-07 | NCT07104383 | |
| An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, idiopathic generalized epilepsy, nervous system disorder, visual epilepsy | Recruiting | Phase 2 | 2025-04-03 | NCT06908356 |